Company intelligence / Profile preview

Foresight Biotherapeutics

New York, New York, United Statesforesight-dx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Foresight Biotherapeutics developed FST‑100, a topical ophthalmic drop combining povidone iodine and dexamethasone. The product showed promise in Phase II studies as a potential first-in-class treatment to address both viral and bacterial infectious conjunctivitis. No marketed therapy existed that could resolve both the signs/symptoms and eradicate adenovirus—the most common cause of viral pink eye—at the time. The company was acquired by Shire plc in August 2015 for $300 million to advance FST‑100 into Phase III trials.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecules (topical ophthalmic drops combining povidone iodine and dexamethasone)
Industry: Biotech

Drug pipeline

1 asset

FST-100

Phase 2

Indications: Infectious conjunctivitis

Beyond the preview

Go deeper on Foresight Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foresight Biotherapeutics.

Explore the full profile